Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis

Journal of the Neurological Sciences

Volumn 143, Issue 1-2, 1996, Pages 91-99

  Bongioanni, Maria Roberta ^a   Durelli, L ^a   Ferrero, B ^a   Imperiale, D ^a   Oggero, A ^a   Verdun, E ^a   Aimo, G ^c   Pagni, R ^c   Geuna, M ^b   Bergamasco, B ^a  

^a Inst Clin Delle Malat Sistema N   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Cytokine; Interferon alpha; Multiple sclerosis

Indexed keywords

BETA 2 MICROGLOBULIN; CD11B ANTIGEN; CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOKINE; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INTERFERON ALFA-2A; LYMPHOCYTES; LYMPHOKINES; MACROPHAGES; MALE; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; PILOT PROJECTS; PLACEBOS; RECOMBINANT PROTEINS;

EID: 10544254263     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(96)00176-1     Document Type: Article

References (50)

1. Antel J., Arnason B.G.W., Medof M.E. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann. Neurol. 5:1979;338-342.
2. Aulitzky W., Gastl G., Aulitzky W.E., Herold M., Kemmler J., Mull B., Frick J., Huber C. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J. Clin. Oncol. 7:1989;1875-1884.
3. Barna B.P., Chou S.M., Jacobs B., Yen-Lieberman B., Ransohoff R.M. Interferon-b impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J. Neuroimmunol. 23:1989;45-53.
4. Basham T.Y., Merigan T.C. Recombinant interferon-g increases HLA-DR synthesis and expression. J. Immunol. 130:1983;1492-1494.
5. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:1988;318-323.
6. Benveniste E.N., Sparacio S.M., Bethea J.R. Tumor necrosis factor-a enhances interferon-g mediated class II antigen expression on astrocytes. J. Neuroimmunol. 25:1989;209-219.
7. Borden, E., Paulnock, D., Spear, G., Byrne, G., Merrit, J., Brown, R. (1986) Biological response modification in man: measurement of interferon-induced proteins. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR Jr, eds. The interferon system: a current review. Austin, TX: University of Texas Press, 1-7.
8. Brinkmann V., Geiger T., Alkan S., Heusser C.H. Interferon-alpha increases the frequency of interferon-gamma-producing human CD4 + T cells. J. Exp. Med. 178:1993;1655-1663.
9. Brook M.G., Chan G., Yap I., Karayiannis P., Lever A.M., Jacyna M., Main J., Thomas H.C. Randomised controlled trial of lymphoblastoid interferon alpha in Europid men with chronic hepatitis B virus infection. BMJ. 299:1989;652-656.
10. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 45((suppl 6)):1995;S16-S21.
11. Durelli L., Poccardi G., Cavallo R. CD8 + highCD11b + low T cells (T suppressor-effector)in multiple sclerosis cerebrospinal fluid are increased during high-dose corticosteroid treatment. J. Neuroimmunol. 31:1991;221-228.
12. Durelli L., Bongioanni M.R., Ferri R., Cavallo R., Aimo G., Ferrero B., Riva A., Bradac G.B., Bergamasco B., Bergamini L. Interferon(IFN)-alpha2a treatment of relapsing/remitting (R/R) multiple sclerosis (MS): disease activity resumes after stopping treatment (abstract). Neurology. 44((suppl 2)):1994;A358.
13. Durelli L., Bongioanni M.R., Cavallo R., Ferrero B., Ferri R., Ferrio M.F., Bradac G.B., Riva A., Vai S., Geuna M., Bergamini L., Bergamasco B. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 44:1994;406-413.
14. Emodi G., Just M., Hernandez R., Hirt H.R. Circulating interferon in man after administration of exogenous human leukocyte interferon. J. Natl. Cancer Inst. 54:1975;1045-1049.
15. Fierz W., Endler B., Reske K., Wekerle H., Fontana A. Astrocytes as antigen presenting cells. 1. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J. Immunol. 134:1985;3785-3793.
16. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., O'Garra A. IL-10 acts on the antigen-presenting cells to inhibit cytokine production by Th1 cells. J. Immunol. 146:1991;3444-3451.
17. Gajewski T.F., Schell R.S., Nau G., Fitch F.W. Regulation of T-cell activation: differences among T-cell subsets. Immunol. Rev. 111:1989;79-110.
18. Gauci L. (1987) Managment of cancer patients receiving interferon alfa-2a. Int. J. Cancer, (suppl. 1): 21-30.
19. Harfast B., Huddlestone J.R., Casali P., Merigan T.C., Oldstone M.B.A. Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J. Immunol. 127:1981;2146-2150.
20. Hennes U., Jucker W., Fischer E.A., Krummenacker T., Palleroni A.V., Trown P.W., Linder-Ciccolunghi S., Rainisio M. The detection of antibodies to recombin,ant interferon alpha-2a in human serum. J. Biol. Stand. 15:1987;231-244.
21. Hirsch R.L., Panitch H.S., Johnson K.P. Lymphocytes from multiple sclerosis patients produce elevated levels of interferon gamma in vitro. J. Clin. Immunol. 5:1985;386-389.
22. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:1993;547-549.
23. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology. 43:1993;662-667.
24. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
25. Inaba K., Kitaura M., Kato T., Watanabe Y., Kawade Y., Muramatsu S. Contrasting effect of a/b- and g-interferons on expression of macrophage Ia antigens. J. Exp. Med. 163:1986;1030-1035.
26. Johns L.D., Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGF-betal enhances the clinical severity of the disease. J. Neuroimmunol. 47:1993;1-8.
27. Katz P., Whalen G., Mitchell R.S., Cupps T.R., Evans M. Modulation of suppression of mitogen-induced T cell-dependent B cell responses by natural killer cells. Clin. Immunol. Immunopathol. 55:1990;148-155.
28. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
29. Maggi E., Parronchi P., Manetti R., Simonelli C., Piccinni M.P., Rugiu F.S., De Carli M., Ricci M., Romagnani S. Reciprocal regulatory effect of IFN-g and IL-4 on the in Th1 and Th2 clones. J. Immunol. 148:1992;2142-2147.
30. Male D., Pryce G. Kinetics of MHC gene expression and mRNA synthesis in brain endothelium. Immunology. 63:1988;37-42.
31. McCarron R.M., Spatz M., Kempski O., Hogan R.N., Muhel L., McFarlin D.E. Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells. J. Neuroimmunol. 147:1986;503-508.
32. Mosmann T.R. Cytokine secretion patterns and cross-regulation of T cell subsets. Immunol. Res. 10:1991;183-188.
33. Noronha A., Toscas A., Mark A., Jensen M.A. Interferon-beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27:1990;207-210.
34. Noronha A., Toscas A., Jensen M.A. Contrasting effects of a, b, and g interferons on nonspecific suppression function in multiple sclerosis. Ann. Neurol. 31:1992;103-106.
35. Olsson T., Wang W.Z., Hojeberg B., Kostulas V., Jiang Y.P., Anderson G., Erke H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-g. J. Clin. Invest. 86:1990;981-985.
36. Olsson T. Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur. J. Neurol. 1:1994;7-19.
37. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma-interferon: exacerbations associated with activation of the immune system. Neurology. 37:1987;1097-1102.
38. Pober J.S., Gimbrone M.A., Cotran R.S., Reiss C.S., Burakoff S.J., Fiers W., Ault K.A. Ia expression by vascular endothelium is inducible by activated T cells and by human g-interferon. J. Exp. Med. 157:1983;1339-1353.
39. Poser et al., 1983.
40. Prineas J.W., Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology. 28:1978;68-75.
41. Quesada, J.R. (1992) Toxicity and side effects of interferons. In: Baron, S., Coppenhaver, D.H., Dianzani, F., Fleischmann, W.R., Hughes, T.K., Klimpel, G.R., Niesel, D.W., Stanton, G.J., Tyring, S.K. Interferon: principles and medical applications. The University of Texas Medical Branch at Department of Microbiology, Galveston, TX. 427-432.
42. Ransohoff R.M., Devajyothi C., Estes M.L., Babcock G., Rudick R.A., Frohman E.M., Barna B.P. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J. Neuroimmunol. 33:1991;103-112.
43. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
44. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
45. Romagnani S. Human Th1 and Th2 subsets: Doubt no more. Immunology Today. 12:1991;256-257.
46. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
47. Shakir S., Byskosh P.V., Reder A.T. Interferon-beta induces interleukin-10 mRNA in mononuclear cells (MNC). (abstract). Neurology. 44((suppl 2)):1994;A 211.
48. Stevens D.B., Gould K.E., Swanborg R.H. Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha / lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J. Neuroimmunol. 51:1994;77-83.
49. Sun J.B., Link H., Xiao B.G., Diener P., Andersson G., Ekre H.P., Linington C., Olsson T. T and B cell responses to myelin oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 146:1991;1490-1495.
50. Suzumura A., Mezitis S.G.E., Gonatas N.K., Sildenberg D.H. MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by g-interferon. J. Neuroimmunol. 15:1987;263-278.